Is It a Monoconal Antibody?

Bighat is working with partners to invent new molecules that have been proven intractable by existing approaches. And then expanding into our own therapeutic efforts, which we think are complementary to what we're seen in the market. The biggest selection criteria for almost all the previous tack has been affinity. So big hatt es pretty heavily leaning into areas where we see affinity is not the same thing as as therapeutic function.